Markets:

Overview

News

Currencies

International

Treasuries

Kazia Therapeutics Limited - American Depositary Shares (NQ:KZIA)

7.465 +0.025 (+0.34%)

Streaming Delayed Price Updated: 10:16 AM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kazia Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >

Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models ↗

October 27, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 27, 2022

Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 14, 2022

Via Benzinga

Kazia Therapeutics (KZIA): Doubling Down on Clinical Development

September 07, 2022

Via ACCESSWIRE

Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases ↗

August 05, 2022

Via Benzinga

Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial ↗

August 01, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 06, 2022

Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

August 10, 2022

During Wednesday, 52 stocks hit new 52-week lows.

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 05, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022 ↗

August 02, 2022

Upgrades

Via Benzinga

U.S. Stocks Turn Negative; Dow Drops Over 100 Points ↗

August 01, 2022

U.S. stocks turned lower toward the end of trading, with the Dow Jones falling more than 100 points on Monday.

Via Benzinga

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday ↗

August 02, 2022

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.

Via Benzinga

Stocks Finding Footing To Kick Off August ↗

August 01, 2022

Stocks are trying to extend last month's impressive trading into August's first session.

Via Talk Markets

Stocks That Hit 52-Week Lows On Monday ↗

August 01, 2022

On Monday, 92 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 01, 2022

Via Benzinga

This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session ↗

August 01, 2022

Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.

Via Benzinga

U.S. Stocks Turn Higher; Crude Oil Tumbles ↗

August 01, 2022

U.S. stocks turned higher midway through trading, after recording gains in the previous session.

Via Benzinga

Why Stocks Are Trading Slightly Lower; U.S. Manufacturing PMI Slips ↗

August 01, 2022

U.S. stocks traded slightly lower this morning, after recording gains in the previous session.

Via Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 01, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

August 01, 2022

Good morning, trader! We're starting off Monday with a breakdown of the biggest pre-market stock movers traders will want to watch!

Via InvestorPlace

Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket ↗

August 01, 2022

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00...

Via Benzinga

KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US

July 20, 2022

KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug...

Via iCrowdNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

July 28, 2022

On Thursday, 108 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 08, 2022

Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million.

Via Benzinga

Kazia Therapeutics (KZIA) Stock Soars on FDA Designation ↗

July 06, 2022

Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment.

Via InvestorPlace

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Kazia Shares Shoot Higher As FDA Grants Rare Pediatric Disease Designation To Brain Cancer Candidate ↗

July 06, 2022

The United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia Therapeutics’ (NASDAQ: KZIA) lead drug Paxalisib for the treatment of atypical...

Via Benzinga

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗

June 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.